Dr Reddy’s Laboratories on Friday said it has launched generic Doxercalciferol injection used for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis, in the US market. According to IQVIA Health data, these products had US sales of around $138 million MAT for the most recent 12 months ending in September 2019, the company said in a statement to the exchanges. Shareholders will closely monitor further developments on this front.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.